As Fig. 3 shows, both AML and CN-AML patients with higher SPAG1 expression also exhibited markedly shorter OS and LFS times than those with poor SPAG1 expression, regardless of the mutation status of FLT3 (Fig. 3a), DNMT3A (Fig. 3b), WT1 (Fig. 3c) or all the three genes (Fig. 3d). This evidence concerns the gene FLT3 and acute myeloid leukemia.